bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world. More information...
According to PR-model, bluebirdbio.com is ranked 1,189,258th in multilingual Wikipedia, in particular this website is ranked 767,389th in English Wikipedia.
The website is placed before wiredglass.ca and after thetangdynasty.org in the BestRef global ranking of the most important sources of Wikipedia.
